# A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B

> **NCT06566248** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** TQA3810 tablets+NUC
- **DRUG:** Placebo+NUC

## Key facts

- **NCT ID:** NCT06566248
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-20
- **Primary completion:** 2024-09
- **Final completion:** 2025-03
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06566248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06566248, "A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06566248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*